The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

A tide change is rippling across healthcare. As industry leaders converged on San Francisco for the 2025 JP Morgan Healthcare conference, they echoed optimism about a renewed stability in healthcare, ...

Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

Looking forward, we expect oil demand to rebound in the coming weeks, averaging 101.4 million barrels per day'.

Kaguya Komatsu has been named the first female CEO of J.P. Morgan Asset Management -Japan, succeeding Shoichi Ohkoshi, who ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...